CL2016001096A1 - Sales de acido 1-(3-metil-2-oxo-2,3-dihidro-1,3-benzoxazol-6-il)-2,4-dioxo-3-[(1r)-4-(trifluorometil)-2,3-dihidro-1h-inden-1-il]-1,2, 3, 4 - tetrahidropirimidin-5-carboxilico. - Google Patents

Sales de acido 1-(3-metil-2-oxo-2,3-dihidro-1,3-benzoxazol-6-il)-2,4-dioxo-3-[(1r)-4-(trifluorometil)-2,3-dihidro-1h-inden-1-il]-1,2, 3, 4 - tetrahidropirimidin-5-carboxilico.

Info

Publication number
CL2016001096A1
CL2016001096A1 CL2016001096A CL2016001096A CL2016001096A1 CL 2016001096 A1 CL2016001096 A1 CL 2016001096A1 CL 2016001096 A CL2016001096 A CL 2016001096A CL 2016001096 A CL2016001096 A CL 2016001096A CL 2016001096 A1 CL2016001096 A1 CL 2016001096A1
Authority
CL
Chile
Prior art keywords
dihydro
benzoxazol
inden
dioxo
oxo
Prior art date
Application number
CL2016001096A
Other languages
English (en)
Inventor
Chantal Furstner
Jens Ackerstaff
Birgit Keil
Britta Olenik
Martin Holger Hinz
Mario Jeske
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CL2016001096A1 publication Critical patent/CL2016001096A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SAL DEL ACIDO 1 -(3-METIL-2-OXO 2,3-DIHIDRO-1,3-BENZOXAZOL-6-IL)-2,4-DIOXO-3-[(1R)-4(TRIFLUOROMETIL)-2,3-DIHIDRO-1H-INDEN-1-IL]-1,2,3,4-TETRAHIDROPIRIMIDIN-5-CARBOXILICO; PROCESO PARA PREPARARLA; MEDICAMENTO QUE LA COMPRENDE; METODO PARA TRATAR; Y USO PARA TRATAR UN TRASTORNO CARDIOVASCULAR, INFLAMATORIO, ALERGICO O FIBROTICO.
CL2016001096A 2013-11-08 2016-05-06 Sales de acido 1-(3-metil-2-oxo-2,3-dihidro-1,3-benzoxazol-6-il)-2,4-dioxo-3-[(1r)-4-(trifluorometil)-2,3-dihidro-1h-inden-1-il]-1,2, 3, 4 - tetrahidropirimidin-5-carboxilico. CL2016001096A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13192177 2013-11-08

Publications (1)

Publication Number Publication Date
CL2016001096A1 true CL2016001096A1 (es) 2016-12-23

Family

ID=49552231

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001096A CL2016001096A1 (es) 2013-11-08 2016-05-06 Sales de acido 1-(3-metil-2-oxo-2,3-dihidro-1,3-benzoxazol-6-il)-2,4-dioxo-3-[(1r)-4-(trifluorometil)-2,3-dihidro-1h-inden-1-il]-1,2, 3, 4 - tetrahidropirimidin-5-carboxilico.

Country Status (32)

Country Link
US (1) US9926305B2 (es)
EP (1) EP3066097B1 (es)
JP (1) JP6446051B2 (es)
KR (1) KR102351418B1 (es)
CN (1) CN105658647B (es)
AP (1) AP2016009181A0 (es)
AU (1) AU2014345599B2 (es)
BR (1) BR112016010253A8 (es)
CA (1) CA2929780C (es)
CL (1) CL2016001096A1 (es)
CY (1) CY1119520T1 (es)
DK (1) DK3066097T3 (es)
EA (1) EA033132B1 (es)
ES (1) ES2645480T3 (es)
HR (1) HRP20171603T1 (es)
HU (1) HUE035021T2 (es)
IL (1) IL245407B (es)
LT (1) LT3066097T (es)
MA (1) MA39020A1 (es)
ME (1) ME02907B (es)
MX (1) MX366848B (es)
MY (1) MY190108A (es)
NO (1) NO3066097T3 (es)
PH (1) PH12016500853B1 (es)
PL (1) PL3066097T3 (es)
PT (1) PT3066097T (es)
RS (1) RS56509B1 (es)
SA (1) SA516371082B1 (es)
SI (1) SI3066097T1 (es)
TN (1) TN2016000170A1 (es)
UA (1) UA117686C2 (es)
WO (1) WO2015067652A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3338780A1 (de) 2016-12-20 2018-06-27 Bayer Pharma Aktiengesellschaft Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind
WO2018197333A1 (en) * 2017-04-27 2018-11-01 Bayer Aktiengesellschaft Selective adrenoreceptor alpha2c receptor antagonists alone, or in combination with chymase inhibitors for use in the treatment and/or prophylaxis of peripheral artery diseases (pad)
WO2022135502A1 (zh) * 2020-12-25 2022-06-30 广东东阳光药业有限公司 多取代的尿嘧啶衍生物及其用途
WO2023194222A1 (en) * 2022-04-05 2023-10-12 Socpra Sciences Santé Humaines S.E.C. Inhibitors of chymase for use in the selective resolution of thrombi in thrombotic or thromboembolic disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001295952A1 (en) * 2000-10-19 2002-04-29 Nippon Kayaku Kabushiki Kaisha Novel remedies or preventives for angiostenosis
AT511788A1 (de) 2011-07-29 2013-02-15 Georg Dr Gaul Vorrichtung zur vorgebbaren anordnung eines stents
EP2822405A4 (en) * 2012-03-05 2015-04-29 Gratuk Technologies Pty Ltd FOOD SUPPLEMENTS
UA112897C2 (uk) * 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань
WO2015067651A1 (de) * 2013-11-08 2015-05-14 Bayer Pharma Aktiengesellschaft Substituierte uracile als chymase inhibitoren

Also Published As

Publication number Publication date
EA201600381A1 (ru) 2016-10-31
CA2929780A1 (en) 2015-05-14
AU2014345599B2 (en) 2019-02-14
EP3066097B1 (de) 2017-08-16
IL245407B (en) 2019-10-31
US20160289220A1 (en) 2016-10-06
EP3066097A1 (de) 2016-09-14
CY1119520T1 (el) 2018-03-07
UA117686C2 (uk) 2018-09-10
PL3066097T3 (pl) 2018-01-31
JP2016535096A (ja) 2016-11-10
ES2645480T3 (es) 2017-12-05
MX2016005971A (es) 2016-08-11
KR20160078980A (ko) 2016-07-05
AU2014345599A1 (en) 2016-05-19
BR112016010253A8 (pt) 2021-06-22
AP2016009181A0 (en) 2016-04-30
IL245407A0 (en) 2016-06-30
US9926305B2 (en) 2018-03-27
JP6446051B2 (ja) 2018-12-26
NO3066097T3 (es) 2018-01-13
CN105658647A (zh) 2016-06-08
WO2015067652A1 (de) 2015-05-14
HK1222171A1 (zh) 2017-06-23
PT3066097T (pt) 2017-11-10
MX366848B (es) 2019-07-26
SA516371082B1 (ar) 2019-05-16
CN105658647B (zh) 2019-09-06
RS56509B1 (sr) 2018-02-28
KR102351418B1 (ko) 2022-01-17
PH12016500853A1 (en) 2016-06-20
HRP20171603T1 (hr) 2017-12-01
HUE035021T2 (en) 2018-03-28
CA2929780C (en) 2022-03-22
BR112016010253A2 (pt) 2017-08-08
TN2016000170A1 (en) 2017-10-06
MA39020A1 (fr) 2017-04-28
NZ719532A (en) 2021-06-25
SI3066097T1 (sl) 2017-12-29
ME02907B (me) 2018-04-20
LT3066097T (lt) 2018-02-12
PH12016500853B1 (en) 2021-03-24
MY190108A (en) 2022-03-29
DK3066097T3 (da) 2017-11-06
EA033132B1 (ru) 2019-08-30

Similar Documents

Publication Publication Date Title
GT201600185A (es) Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
CL2018001560A1 (es) Moléculas de anticuerpos para pd-1 y sus usos
CL2016002573A1 (es) Compuesto de ciclopropanamina y sus usos.
CL2017003089A1 (es) Formas de dosificación sólidas de palbociclib
CL2017000888A1 (es) Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
CL2014002880A1 (es) Compuestos derivados de heterociclos nitrogenados o sus sales, inhibidores selectivos de la pde2a; medicamento que los comprende; y su uso para la profilaxis y tratamiento de la esquizofrenia.
LT3472153T (lt) Pirimidin-2-ilamino-1h-pirazolai kaip lrrk2 inhibitoriai, skirti naudoti neurodegeneracinių sutrikimų gydyme
CL2015002279A1 (es) Amidas heterocíclicas como inhibidores de cinasas
EP3317842A4 (en) GAMIFICATION SYSTEMS AND METHOD FOR IMPROVED HEALTH CARE RESULTS
MX384909B (es) Un anticuerpo anti-tau para usarse al tratar una tauopatía.
FR3025902B1 (fr) Souris vibrante multi-dimensions
CL2017000944A1 (es) Compuesto heterocíclico
BR112017008154A2 (pt) construção de gerenciamento de luz
CL2016001096A1 (es) Sales de acido 1-(3-metil-2-oxo-2,3-dihidro-1,3-benzoxazol-6-il)-2,4-dioxo-3-[(1r)-4-(trifluorometil)-2,3-dihidro-1h-inden-1-il]-1,2, 3, 4 - tetrahidropirimidin-5-carboxilico.
CL2015002181A1 (es) Tratamiento de formas progresivas de esclerosis múltiple con laquinimod.
HUE042175T2 (hu) Olaj szénszál prekurzor akrilszálhoz, olaj kompozíció szénszál prekurzor akrilszálhoz, olaj kezelõfolyadék szénszál prekurzor akrilszálhoz, és szénszál prekurzor akrilszál nyaláb
EP3526819C0 (en) ENERGY STORAGE DEVICE THAT IS ALSO AN OPTOELECTRONIC DEVICE
CL2016000984A1 (es) Sistema y método para la implementación de consultas de búsqueda multi-facetadas
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
MX2015012455A (es) Metodo para el tratamiento de la enfermedad de higado graso.
CL2015003668A1 (es) Método de tratamiento de trastornos neurodegenerativos.
BR112016011554A2 (pt) Uso de brometo para minimizar ou prevenir a indução de inanição relacionada ao estresse ou inanição relacionada à ansiedade em um animal durante, ou em conclusão de, uma prática de comercialização ou gestão
Chiarella et al. Computational methods for derivatives with early exercise features
TH178678A (th) เกลือแบบใหม่ของ 1-(3-เมธิล-2-ออกโซ-2,3-ไดไฮโดร-1,3-เบนซอกซาโซล-6-อิล)-2,4- ไดออกโซ-3-[(1r)-4-(ไตรฟลูออโรเมธิล)-2,3-ไดไฮโดร-1h-อินดิน-1-อิล]-1,2,3,4- เตตระไฮโดรไพริมิดีน-5-คาร์บอกซิลิกแอซิดและการใช้เกลือดังกล่าว
CL2013001170A1 (es) Un metodo para proveer un servicio de administracion de membresia multinivel susucrita en linea y realimenta la ganancia de acuerdo con una regla predeterminada cuando se vende un producto o servcio.